




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 401/14, A61K 31/55, C07D 401/04, A61K 31/495, 31/44 // (C07D 401/14, 241:00, 221:00, 213:00)	A1	(11) International Publication Number: WO 98/57960 (43) International Publication Date: 23 December 1998 (23.12.98)
(21) International Application Number: PCT/US98/11495 (22) International Filing Date: 15 June 1998 (15.06.98) (30) Priority Data: 08/877,741 17 June 1997 (17.06.97) US (71) Applicants: SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033 (US). PHARMACOPEDIA, INC. [US/US]; 101 College Road East, Princeton, NJ 08540 (US). (72) Inventors: COOPER, Alan, B.; 23 Natalie Drive, West Caldwell, NJ (US). DOLL, Ronald, J.; 126 Union Avenue, Maplewood, NJ 07040 (US). GIRIJAVALLABHAN, Viyyoor, M.; 10 Maplewood Drive, Parsippany, NJ 07054 (US). GANGULY, Ashit; 96 Cooper Avenue, Upper Montclair, NJ 07043 (US). READER, John, C.; 744 Newmarket Road, Cambridge CB5 8RT (GB). BALDWIN, John, J.; 621 Gypsy Hill Circle, Gwynedd Valley, PA 19437 (US). HUANG, Chia-yu; 65-15 Ravens Crest Drive, Plainsboro, NJ 08536 (US).		(74) Agents: MANN, Arthur et al.; Schering-Plough Corporation, Patent Dept., K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US). (81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>

(54) Title: BENZPYRIDO CYCLOHEPTANE COMPOUNDS USEFUL FOR INHIBITION OF FARNESYL PROTEIN TRANSFERASE

(57) Abstract

Novel compounds of Formula (1.0) are disclosed. Also disclosed is a method of inhibiting farnesyl protein transferase function and therefore inhibiting the abnormal growth of cells. The method comprises administering a compound of formula (1.0) to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammal such as a human being.



(1.0)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

BENZPYRIDO CYCLOHEPTANE COMPOUNDS USEFUL FOR INHIBITION OF FARNESYL PROTEIN TRANSFERASE

5


BACKGROUND

WO 95/10516, published April 20, 1995 discloses tricyclic compounds useful for inhibiting farnesyl protein transferase.

10 In view of the current interest in inhibitors of farnesyl protein transferase, a welcome contribution to the art would be compounds useful for the inhibition of farnesyl protein transferase. Such a contribution is provided by this invention.

15 SUMMARY OF THE INVENTION

This invention provides compounds useful for the inhibition of farnesyl protein transferase (FPT). The compounds of this invention are represented by the formula:



20 or a pharmaceutically acceptable salt or solvate thereof, wherein:

a represents N or NO⁻;

25 R^a, R^b, R^c, and R^d are the same or different, and are selected from the group consisting of H, halo, alkyl, and alkoxy, with the proviso that at least one, but not more than two of R^a, R^b, R^c and R^d are H;

the dotted line (---) represents an optional double bond;

R is selected from the group consisting of H, -S(O)₂R¹,


-S(O)₂NR¹R², -C(O)R¹, and -C(O)NR¹R², wherein R¹ and R² are

30 independently selected from the group consisting of H, alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, (C₃-C₇) cycloalkyl,

- 2 -

- cycloalkylalkyl, heterocycloalkyl, substituted alkyl, substituted aryl, substituted arylalkyl, substituted heteroaryl, substituted heteroarylalkyl, substituted (C₃-C₇) cycloalkyl, substituted cycloalkylalkyl, substituted heterocycloalkyl, wherein said
- 5 substituted groups have one or more substituents selected from: alkyl, alkoxy, aralkyl, heteroarylalkyl, -NO₂, alkyloxyalkyl, alkyloxyalkyloxyalkyl, C₃-C₇ cycloalkyl, aryl, -CN, heteroaryl, heterocycloalkyl, =O, -OH, amino, substituted amino, nitro and halo;
- 10 R^e and R^f are independently selected from H, alkyl, alkyloxyalkyl, alkyloxyalkyloxyalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, (C₃-C₇) cycloalkyl, cycloalkylalkyl, heterocycloalkyl, substituted alkyl, substituted alkyloxyalkyl, substituted alkyloxyalkyloxyalkyl, substituted aryl, substituted
- 15 arylalkyl, substituted heteroaryl, substituted heteroarylalkyl, substituted (C₃-C₇) cycloalkyl, substituted cycloalkylalkyl, substituted heterocycloalkyl, wherein said substituted groups have one or more substituents selected from: alkyl, alkoxy, aralkyl, heteroarylalkyl, -NO₂, alkyloxyalkyl,
- 20 alkyloxyalkyloxyalkyl, C₃-C₇ cycloalkyl, aryl, -CN, heteroaryl, heterocycloalkyl, =O, -OH, amino, substituted amino, nitro and halo; or R^e is selected from the group consisting of H, alkyl and aryl and R^f is represented by —(CH₂)_n—R¹⁵, wherein n is an integer from 0 to 8 and R¹⁵ is selected from -C(O)NH₂, -SO₂NH₂,
- 25 aryl, heteroaryl, cycloalkyl, heterocycloalkyl, optionally substituted by alkyl, alkoxy, aralkyl, heteroarylalkyl, -NO₂, alkyloxyalkyl, alkyloxyalkyloxyalkyl, C₃ - C₇ cycloalkyl, aryl,

- 4 -



5 The compounds of this invention: (i) potently inhibit
 farnesyl protein transferase, but not geranylgeranyl protein
 transferase I, in vitro; (ii) block the phenotypic change induced
 by a form of transforming Ras which is a farnesyl acceptor but
 not by a form of transforming Ras engineered to be a
 10 geranylgeranyl acceptor; (iii) block intracellular processing of
 Ras which is a farnesyl acceptor but not of Ras engineered to be
 a geranylgeranyl acceptor; and (iv) block abnormal cell growth
 in culture induced by transforming Ras.

15 The compounds of this invention inhibit farnesyl protein
 transferase and the farnesylation of the oncogene protein Ras.
 Thus, this invention further provides a method of inhibiting
 farnesyl protein transferase, (e.g., ras farnesyl protein
 transferase) in mammals, especially humans, by the
 administration of an effective amount of the tricyclic compounds
 20 described above. The administration of the compounds of this
 invention to patients, to inhibit farnesyl protein transferase, is
 useful in the treatment of the cancers described below.

25 This invention provides a method for inhibiting or treating
 the abnormal growth of cells, including transformed cells, by
 administering an effective amount of a compound of this
 invention. Abnormal growth of cells refers to cell growth
 independent of normal regulatory mechanisms (e.g., loss of
 contact inhibition). This includes the abnormal growth of: (1)
 tumor cells (tumors) expressing an activated Ras oncogene; (2)
 30 tumor cells in which the Ras protein is activated as a result of

- 5 -

oncogenic mutation in another gene; and (3) benign and malignant cells of other proliferative diseases in which aberrant Ras activation occurs.

5 This invention also provides a method for inhibiting or treating tumor growth by administering an effective amount of the tricyclic compounds, described herein, to a mammal (e.g., a human) in need of such treatment. In particular, this invention provides a method for inhibiting or treating the growth of tumors expressing an activated Ras oncogene by the
10 administration of an effective amount of the above described compounds. Examples of tumors which may be inhibited or treated include, but are not limited to, lung cancer (e.g., lung adenocarcinoma), pancreatic cancers (e.g., pancreatic carcinoma such as, for example, exocrine pancreatic carcinoma), colon
15 cancers (e.g., colorectal carcinomas, such as, for example, colon adenocarcinoma and colon adenoma), myeloid leukemias (for example, acute myelogenous leukemia (AML)), thyroid follicular cancer, myelodysplastic syndrome (MDS), bladder carcinoma, epidermal carcinoma, breast cancer and prostate cancer.

20 It is believed that this invention also provides a method for inhibiting or treating proliferative diseases, both benign and malignant, wherein Ras proteins are aberrantly activated as a result of oncogenic mutation in other genes--i.e., the Ras gene itself is not activated by mutation to an oncogenic form--with
25 said inhibition or treatment being accomplished by the administration of an effective amount of the tricyclic compounds described herein, to a mammal (e.g., a human) in need of such treatment. For example, the benign proliferative disorder neurofibromatosis, or tumors in which Ras is activated due to
30 mutation or overexpression of tyrosine kinase oncogenes (e.g., neu, src, abl, lck, and fyn), may be inhibited or treated by the tricyclic compounds described herein.

The tricyclic compounds useful in the methods of this invention inhibit or treat the abnormal growth of cells. Without
35 wishing to be bound by theory, it is believed that these compounds may function through the inhibition of G-protein function, such as ras p21, by blocking G-protein isoprenylation, thus making them useful in the treatment of proliferative

- 6 -

diseases such as tumor growth and cancer. Without wishing to be bound by theory, it is believed that these compounds inhibit ras farnesyl protein transferase, and thus show antiproliferative activity against ras transformed cells.

5

DETAILED DESCRIPTION OF THE INVENTION

As used herein, the following terms are used as defined below unless otherwise indicated:

10 MH⁺-represents the molecular ion plus hydrogen of the molecule in the mass spectrum;

Bu-represents butyl;


Boc represents a tert-butoxycarbonyl group

Et-represents ethyl;


Me-represents methyl;

15 Ph-represents phenyl;

benzotriazol-1-yloxy represents



1-methyl-tetrazol-5-ylthio represents



20 alkyl-(including the alkyl portions of alkoxy, alkylamino and dialkylamino)-represents straight and branched carbon chains and contains from one to twenty carbon atoms, preferably one to six carbon atoms;

25 alkyloxyalkyl represents alkyl bound to an oxygen atom, which in turn is bound to alkyl.

alkyloxyalkyloxyalkyl represents alkyl bound to oxygen, which in turn is bound to alkyl, which in turn is bound to oxygen, which in turn, is bound to alkyl (e.g., CH₂CH₂OCH₂CH₂OCH₂CH₃)

30 alkanediyl-represents a divalent, straight or branched hydrocarbon chain having from 1 to 20 carbon atoms, preferably 1 to 6 carbon atoms, the two available bonds being

- 7 -

from the same or different carbon atoms thereof, e.g., methylene, ethylene, ethylidene,

-CH₂CH₂CH₂-, -CH₂CHCH₃, -CHCH₂CH₃, etc.

5 cycloalkyl-represents saturated carbocyclic rings
branched or unbranched of from 3 to 20 carbon atoms,
preferably 3 to 7 carbon atoms;

10 heterocycloalkyl-represents a saturated, branched or
unbranched carbocyclic ring containing from 3 to 15 carbon
atoms, preferably from 4 to 6 carbon atoms, which carbocyclic
ring is interrupted by 1 to 3 hetero groups selected from -O-,
-S- or -NR¹⁰-, wherein R¹⁰ is H, alkyl, aryl, or arylalkyl
(suitable heterocycloalkyl groups including 2- or 3-
tetrahydrofuranyl, 2- or 3- tetrahydrothienyl, 2-, 3- or 4-
piperidiny, 2- or 3-pyrrolidiny, 1-, 2- or 3-piperiziny, 2- or 4-
15 dioxany, etc.);

alkenyl-represents straight and branched carbon chains
having at least one carbon to carbon double bond and containing
from 2 to 12 carbon atoms, preferably from 2 to 6 carbon atoms
and most preferably from 3 to 6 carbon atoms;

20 alkynyl-represents straight and branched carbon chains
having at least one carbon to carbon triple bond and containing
from 2 to 12 carbon atoms, preferably from 2 to 6 carbon atoms;


aryl (including the aryl portion of aryloxy and aralkyl)-
represents a carbocyclic group containing from 6 to 15 carbon
25 atoms and having at least one aromatic ring (e.g., aryl is a
phenyl ring), with all available substitutable carbon atoms of
the carbocyclic group being intended as possible points of
attachment, said carbocyclic group being optionally substituted
(e.g., 1 to 3) with one or more of halo, alkyl, hydroxy, alkoxy,
30 phenoxy, CF₃, amino, alkylamino, dialkylamino, -COOR¹⁰ or -NO₂;
and

halo-represents fluoro, chloro, bromo and iodo; and

heteroaryl-represents cyclic groups, optionally
substituted, and having at least one heteroatom selected from O,
35 S or N, said heteroatom interrupting a carbocyclic ring structure
and having a sufficient number of delocalized pi electrons to
provide aromatic character, with the aromatic heterocyclic
groups preferably containing from 2 to 14 carbon atoms, e.g.,


- 8 -

triazolyl, 2-, 3- or 4-pyridyl or pyridyl N-oxide (optionally substituted with R^3 and R^4), wherein pyridyl N-oxide can be represented as:




- 5 The following solvents and reagents are referred to herein by the abbreviations indicated: tetrahydrofuran (THF); CDI (carbonyl di-imidazole) ethanol (EtOH); methanol (MeOH); acetic acid (HOAc or AcOH); ethyl acetate (EtOAc); N,N-dimethylformamide (DMF); trifluoroacetic acid (TFA);
- 10 trifluoroacetic anhydride (TFAA); 1-hydroxybenzotriazole (HOBT); m-chloroperbenzoic acid (MCPBA); triethylamine (Et_3N); diethyl ether (Et_2O); ethyl chloroformate ($ClCO_2Et$); 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride (DEC); disobutylaluminum hydride (DIABL); and 4-
- 15 methylmorpholine (NMM).

The positions in the tricyclic ring system are:




Preferred halo atoms for R^a , R^b , R^c , and R^d in Formula 1.0 are selected from: Br, Cl or I, with Br and Cl being preferred.

- 20 Compounds of Formula 1.0 include compounds of the formula:



Compounds of Formula 1.0 include compounds of the formula:

- 9 -




















Preferably, for the compounds of this invention, R^a , R^b , R^c and R^d are selected from halo, preferably Br or Cl, and more preferably, R^a is Br and R^c is Cl. Preferably, only one of R^a , R^b , R^c , and R^d is H.


Preferably, in Formula (1.0a), R^a is Br, R^c is Cl, and R^b or R^d is halo. More preferably, in Formula (1.0a), R^a is Br, R^c is Cl, and R^b or R^d is Br.

Preferably, for the compounds of this invention, one of R^e or R^f is H, and the other is $-(CH_2)_n-R^{15}$, wherein R^{15} is selected from: alkyloxyalkyl, NHBoc,

- 10 -




- 11 -




Preferably, for the compounds of this invention, the optional double bond between positions 5 and 6 (i.e., C5-C6) in the tricyclic system is absent.

Also, preferably, for the compounds of this invention, substituent a in Ring I represents N.


Thus, compounds of the invention include compounds of the formulas:




(200)



(201)




(202)




(203)


- 12 -




(204)




(205)




(206)




(207)



(208)




(209)




(210)


- 13 -




(211)




(212)




(213)



(214)




(215)




(217)


- 14 -




(219)




(220)




(221)



(222)




(223)




(224)


- 15 -




- 16 -




(226)




(227)




(228)




(229)



(230)




(231)




(232)

- 17 -


The following compounds, which may be prepared according to the methods disclosed in WO96/31478 and/or WO95/15016, are also within the scope of the present invention:




233




234




235



236




237




238


- 19 -




239




240




241



242









243














244




- 20 -




- 21 -












265




266




267



268



269



270

- 25 -

Lines drawn into the ring systems indicate that the indicated bond may be attached to any of the substitutable ring carbon atoms.

Certain compounds of the invention may exist in different isomeric (e.g., enantiomers and diastereoisomers) forms. The invention contemplates all such isomers both in pure form and in admixture, including racemic mixtures. Enol forms are also included.

Certain tricyclic compounds will be acidic in nature, e.g. those compounds which possess a carboxyl or phenolic hydroxyl group. These compounds may form pharmaceutically acceptable salts. Examples of such salts may include sodium, potassium, calcium, aluminum, gold and silver salts. Also contemplated are salts formed with pharmaceutically acceptable amines such as ammonia, alkyl amines, hydroxyalkylamines, N-methylglucamine and the like.

Certain basic tricyclic compounds also form pharmaceutically acceptable salts, e.g., acid addition salts. For example, the pyrido-nitrogen atoms may form salts with strong acid, while compounds having basic substituents such as amino groups also form salts with weaker acids. Examples of suitable acids for salt formation are hydrochloric, sulfuric, phosphoric, acetic, citric, oxalic, malonic, salicylic, malic, fumaric, succinic, ascorbic, maleic, methanesulfonic and other mineral and carboxylic acids well known to those in the art. The salts are prepared by contacting the free base form with a sufficient amount of the desired acid to produce a salt in the conventional manner. The free base forms may be regenerated by treating the salt with a suitable dilute aqueous base solution such as dilute aqueous NaOH, potassium carbonate, ammonia and sodium bicarbonate. The free base forms differ from their respective salt forms somewhat in certain physical properties, such as solubility in polar solvents, but the acid and base salts are otherwise equivalent to their respective free base forms for purposes of the invention.


- 26 -

All such acid and base salts are intended to be pharmaceutically acceptable salts within the scope of the invention and all acid and base salts are considered equivalent to the free forms of the corresponding compounds for purposes of the invention.

Compounds of the invention may be prepared according to the procedures described in WO 96/30363, published October 3, 1996, WO96/31478, published October 10, 1996, WO 95/10516 published April 20, 1995, copending Application Serial No. 08/410,187 filed March 24, 1995, copending Application Serial No. 08/577,951 filed December 22, 1995, and copending Application Serial No. 08/615,760 filed March 13, 1996; the disclosures of each being incorporated herein by reference thereto; and according to the procedures described below.

Compounds of the formula 1.0a can be prepared from a tricyclic hydroxy compound (2.0) as shown in Reaction Scheme 1.

Reaction Scheme 1




Compound (2.0), which may be prepared as described in WO 95/10516, published April 20, 1995 and in U.S. 5,151,423, can be chlorinated with a chlorinating agent, e.g., thionyl chloride, as described therein to form Compound (2.1). Compound (2.1) may then be reacted with a suitably substituted piperazine to form Compound (1.0a). The reaction with the piperazine is carried out in a suitable solvent, e.g., DMF or THF in

- 27 -

the presence of a base, e.g., triethylamine, at a temperature of from 0 to 80 C for 1 - 24 hours, then added to water, extracted with a suitable solvent, e.g., ethyl acetate, and chromatographed on silica gel.

- 5 Alternatively, compounds of the formula (1.0a) can be generally prepared as shown in Reaction Scheme 2.

Reaction Scheme 2



5

Compound (2.1) is reacted with ethylpiperazine-3-carboxylate to form Compound (2.1a). The reaction with the piperazine is carried out in a suitable solvent, e.g., DMF or THF in the presence of a base, e.g., triethylamine, at a temperature of from 0 to 80 °C for 1 - 24 hours, then added to water, extracted with a suitable solvent, e.g., ethyl acetate, and chromatographed on silica gel. Compound (2.1a) can then be reacted with a suitable protecting group, such as the Boc group, utilizing di-tert.butylidicarbonate to form Compound (2.1b). Compound (2.1b) is subjected to step a (replacement of OEt with NR^eR^f), discussed below, to form Compound (3.0). Compound (3.0) can then be subjected to a standard deprotection reaction to remove the Boc group, thus forming Compound (3.1). Compound (3.1)

- 29 -

can then optionally be subjected to reaction step (b) (substitution of the nitrogen of the piperazine with R) if it is desired that R be other than H. Steps (a) and (b) may be carried out in any sequence. When Compound (2.1a) is subjected to
5 reaction step b first (i.e., forming Compound (3.2)), the use of a protecting group is generally not required.

Step (a) is carried out by reacting Compound (2.1b) or Compound (3.2) with LiOH in water with a suitable co-solvent, such as methanol, to convert the $-C(O)OEt$ group to $-C(O)OH$. This
10 carboxylic acid intermediate can then be reacted with a suitable NHR^eR^f amine compound (wherein R^e and R^f are as defined above) in the presence of HOBt and N-methylmorpholine and a coupling agent, such as DEC or DCC in a suitable solvent, e.g., DMF at a temperature of from 0 to 80 °C for 1 - 24 hours, then added
15 to water, extracted with a suitable solvent, e.g., ethyl acetate, and chromatographed on silica gel.


Step (b) can be carried out in the following manner, depending on the R substituent:

For compounds of the formula (1.0a) wherein R and the
20 nitrogen atom to which it is attached together comprise an amide, e.g., where R is $-C(O)-alkyl$, step (b) can be carried out by reacting the amine (2.1a or 3.1) with a carboxylic acid of the formula $RA-C(O)-OH$, wherein $RA-C(O)-$ is R, in the presence of a coupling agent such as DEC, CDI or DCC. The reaction is typically
25 carried out in a suitable organic solvent such as DMF, THF or CH_2Cl_2 at a temperature of -10° to $100^\circ C$, preferably at 0° to $50^\circ C$, and most preferably at about room temperature. When the coupling agent is DCC or DEC, the reaction is preferably conducted in the presence of HOBt and N-methylmorpholine.

30 Alternatively, the amine (2.1a or 3.1) can be reacted with a compound of the formula $R-L$, wherein R is as defined above and L is a leaving group, such as Cl, Br, I, $-O-C(O)-R^B$ wherein R^B is C_1-C_6 alkyl or phenyl, or a sulfonate group of the formula $-OSO_2-R^C$, wherein R^C is selected from C_1-C_6 alkyl, phenyl, CF_3 ,
35 tolyl and p-bromophenyl, to form a compound of the formula (1.0a). The reaction is carried out in the presence of a base, preferably a tertiary amine base, such as Et_3N , DMAP, pyridine or Hünigs base.

- 30 -

For compounds of Formula 1.0a wherein: R is $-C(O)-CH_2-R^D$, wherein R^D is a piperidine of the formula:



and R^E represents $-C(O)NH_2$ (i.e., a carboxamide), step (b) can be carried out by reacting the amine (2.1a or 3.1) with a protected piperidine, i.e., $C(O)CH_2$ -piperidine-N-Boc in the presence of a coupling agent such as DEC, CDI or DCC. The reaction is typically carried out in a suitable organic solvent such as DMF, THF or CH_2Cl_2 at a temperature of -10° to $100^\circ C$, preferably at 0° to $50^\circ C$, and most preferably at about room temperature. When the coupling agent is DCC or DEC, the reaction is preferably conducted in the presence of HOBT and N-methylmorpholine. The above described Boc-piperidine compound is then de-protected with a suitable acid, such as trifluoroacetic acid, to provide a piperidine wherein the nitrogen is unsubstituted. The above described unsubstituted piperidine is reacted with an excess of urea in water. This reaction can be run with about 4 to about 10 equivalents of urea relative to the unsubstituted piperidine starting reactant. Generally, about 10 equivalents of urea can be used. The reaction is run for about 3 to about 68 hours. Generally, the reaction can be run for about 60 to 70 hours. The reaction is usually run at the reflux temperature of the reaction mixture. This can range from about 98° to about $100^\circ C$. The amount of the unsubstituted piperidine starting reactant relative to water may typically vary from about 0.025g/ml to about 0.6g/ml, and can generally be about 0.1 g/ml.


For preparing compounds of the formula (1.0a) wherein R is $-C(O)-NH-R^G$, R^G being an alkyl, cycloalkyl, or heterocycloalkyl group, step (b) is carried out by reacting a compound of the formula (2.1a or 3.1) with an isocyanate of the formula $R^G-N=C=O$, in a suitable solvent such as DMF, THF or CH_2Cl_2 using methods well known in the art.

Alternatively, the amine (2.1a or 3.1) is reacted with phosgene to form a chloroformate intermediate of the formula (5.0), as shown in Reaction Scheme 4. The chloroformate (5.0) is

- 31 -

generally not isolated and is reacted with an amine of the formula R^G-NH_2 , wherein R^G is as defined above, to form a compound of the formula (1.0a), wherein R is $-C(O)-NH-R^G$.

5

Reaction Scheme 4

10

When R is $S(O)_2R^1$, step b can be carried out by dissolving Compound (3.1) in an appropriate solvent such as DMF or THF. A base is added such as triethylamine, and the appropriate alkylsulfonylchloride ($R^1-S(O)_2Cl$), prepared by methods known in the art, is added to the reaction mixture at 0°C to ambient temperature with stirring. After 1-24 hours, the reaction mixture is added to water and the product extracted with a suitable solvent such as ethylacetate. The crude reaction product can then be chromatographed on a silica gel column.

15

When R is $S(O)_2NR^1R^2$, step b can be carried out by dissolving Compound 3.1 in an appropriate solvent such as DMF or THF. A base is added such as triethylamine, and the appropriate alkylaminosulfonyl chloride ($R^1R^2N-S(O)_2Cl$), prepared by methods known in the art, is added to the reaction mixture at 0°C to ambient temperature with stirring. After 1-24

20

25

- 32 -


hours, the reaction mixture is added to water and the product extracted with a suitable solvent such as ethylacetate. The crude reaction product can then be chromatographed on a silica gel column.

5

Alternatively, compounds of the formula (1.0a) can be generally prepared as shown in Reaction Scheme 5.

Reaction Scheme 5


10



Compound (6.0) is reacted with di-tert-butyl-dicarbonate to form Compound (6.1). Compound (6.1) is reacted with NHR^eR^f in the presence of DEC and HOBt to form Compound (6.2). Compound (6.2) is treated with TFA to form Compound (6.3). Compound (6.3) is reacted with the tricyclic compound (6.4) to form Compound (6.5). Compound (6.5) is subjected to the treatment(s) described above for step (b) to obtain Compound (6.6).

- 5 Compounds of formula (1.0a) in the R-enantiomeric form may be prepared as shown below in reaction schemes 6 and 7.


REACTION SCHEME 6



- Compound (6.7) is hydrogenated under pressure, e.g., at a pressure of 30 to 100 psi, preferably 50 psi, in the presence of a Pd/C catalyst, e.g., 10% Pd/C. The hydrogenation is carried out at temperatures of 20°C to 30°C in ethanol. The hydrogenated product is subsequently reacted with KOH in water at ambient

5 temperature to yield Compound (6.8). Compound (6.8) is reacted with 3 equivalents of R(-)camphor sulfonic acid ("CSA") at ambient temperature and recrystallized several times in water to yield a dicamphor sulfonic salt, Compound (6.9). Compound (6.9) is reacted with (Boc)₂O (di-tert-butyl dicarbonate) in a methanol/H₂O
10 solution at ambient temperature to yield Compound (6.10). Compound (6.10) is reacted with sulfonyl chloride in DMF at 0°C and subsequently reacted with acetonitrile in pyridine at 0°C and allowed to warm to ambient temperature to yield Compound (6.11). Compound (6.11) is reacted with NHR^eR^f in methylene
15 chloride at ambient temperature to form Compound (6.12). Compound (6.12) is reacted with either an isocyanate, R¹-N=C=O, or a carboxylic acid, R¹CO₂H, wherein R¹ is as defined above in formula (1.0), to form Compound (6.13), where R = -C(O)NHR¹ or C(O)R¹. The reaction with R¹-N=C=O or R¹CO₂H is carried out in
20 either DMF or dichloromethane at ambient temperature. When R¹CO₂H is used, the reaction is preferably carried out in the presence of a coupling agent, e.g., DEC. The reactions converting Compound (6.11) to Compound (6.12) and converting Compound (6.12) to Compound (6.13) may be carried out as a one pot
25 synthesis. Compound (6.13) is deprotected with TFA in methylene chloride at ambient temperature to form Compound (6.14). Compound (6.14) is reacted with Compound (6.15) in DMF at ambient temperature to form Compound (6.16).

REACTION SCHEME 7



5


Compound (6.9), prepared as shown above in Scheme 6, is reacted with benzyl chloroformate (CBZ-Cl) in 50% dioxane water at ambient temperature to form a benzyloxycarbonyl compound, which is subsequently reacted with (Boc)₂O to form Compound (6.17). Compound (6.17) is hydrogenated under pressure, e.g., at a pressure of 30 to 100 psi, preferably 50 psi, in the presence of a Pd/C catalyst at ambient temperature to form Compound (6.18). Compound (6.18) is reacted with Compound (6.19) in DMF at ambient temperature to form Compound (6.20). Compound (6.20) is reacted with NHR^eR^f with DEC/HOBt in DMF at ambient temperature to form Compound (6.21). Compound (6.21) is deprotected with TFA at ambient temperature and then reacted with either an isocyanate, R¹-N=C=O, or a carboxylic acid, R¹CO₂H, where R¹ is as defined above in formula (1.0), to form Compound (6.22), where R is -C(O)NHR¹ or -C(O)R¹. The reaction with R¹-N=C=O or R¹CO₂H is carried out in either DMF or dichloromethane at ambient temperature. When R¹CO₂H is used, the reaction is

20

- 5 preferably carried out in the presence of a coupling agent, e.g., DEC. The reactions converting Compound (6.20) to Compound (6.21) and converting Compound (6.21) to Compound (6.22) may be carried out as a one pot synthesis.

- 37 -

Compound (1.0b), wherein R is H, can be prepared according to the following reaction scheme:



5


Compound (7.0) is treated with cyanuric fluoride and pyridine in CH₂Cl₂. The resulting acid fluoride is subsequently reacted with NHR^eR^f in the presence of triethylamine in CH₂Cl₂ to obtain Compound (7.1). Compound (7.1) is reacted with piperidine in CHCl₃ to yield an amine which is subsequently reacted with bromoacetyl bromide and 2,6-lutidine in CH₂Cl₂ to form Compound (7.2). Compound (7.2) is treated with trifluoroacetic acid in CH₂Cl₂, followed by treatment with diisopropylethylamine in DMSO to form the keto-substituted piperazine compound, Compound (7.2a). Compound (7.2a) is then reacted with tricyclic compound (7.3) to give Compound (1.0b), wherein R is H.

10

15

- 38 -


Compound (1.0b), wherein R is not H, can be prepared according to the following reaction scheme:



5 Compound (8.0) is reacted with R(O)H , e.g., valeraldehyde in 2% acetic acid/MeOH to obtain Compound (8.1). Compound (8.1) is reacted with chloroacetyl chloride in the presence of 2,6-lutidine in DMF to obtain Compound (8.2). Compound (8.2) is treated with trifluoroacetic acid in CH_2Cl_2 , followed by treatment with diisopropylethylamine in DMSO to form the keto-substituted piperazine compound, Compound (8.2a). Compound (8.2a) is then reacted with tricyclic compound and reaction with the tricyclic compound (8.3) to obtain Compound (8.4).

15 Compounds of Formula 1.0 wherein substituent a is NO can be made from a tricyclic ketone by using procedures well known to those skilled in the art, as shown in the following scheme:

- 39 -



For example, the ketone (9.0) can be reacted with m-chloroperoxybenzoic acid in a suitable organic solvent, e.g., dichloromethane (usually anhydrous) or methylene chloride, at a suitable temperature, to produce NO-substituted compound (9.1). Generally, the organic solvent solution of ketone (9.0) is cooled to about 0°C before the m-chloroperoxybenzoic acid is added. The reaction is then allowed to warm to room temperature during the reaction period. Compound (9.1) can be recovered by standard separation means. For example, the reaction mixture can be washed with an aqueous solution of a suitable base, e.g., saturated sodium bicarbonate or NaOH (e.g., 1N NaOH), and then dried over anhydrous magnesium sulfate. The solution containing the product can be concentrated in vacuo. The product can be purified by standard means, e.g., by chromatography using silica gel (e.g., flash column chromatography). Compound (9.1) is converted to the hydroxy compound (9.2) by conventional means, e.g., by reacting it with NaBH₄ in methanol. Compound (9.2) is converted to the corresponding chlorinated compound (9.3) by conventional means, e.g., by reacting it with SOCl₂. Compound (9.3) is then reacted with a suitably substituted piperazine as described above, to give the desired compound.


- 40 -

Compounds useful in this invention are exemplified by the following examples, which should not be construed to limit the scope of the disclosure.

5

EXAMPLE 1


The following compound was prepared according to the procedure described below



10

Step 1A

15



Compound A is prepared as follows:

20 Dissolve 5.25 g (25.85 mmol) of 2- piperazine
carboxylic acid.2HCl in 160 ml of 1:1 dioxane/H₂O, and adjust the pH to
11 with 50% NaOH (aq.). Slowly add (in portions) a solution of 7.21 g
(29.28mmol) of BOC-ON in 40 ml of dioxane while maintaining the pH at
11 with 50% NaOH (aq.) during the addition. Stir at room temperature for


- 41 -

5 hours, then cool to 0 °C and adjust to pH/9.5 with 50% NaOH(aq.). Slowly add (in portions) a solution of 7.34 g (28.37mmol) of FMOC-Cl in 40 mL of dioxane, maintaining a pH of 9.5 during the addition with 50% NaOH. Warm the mixture to room temperature and stir for 20 hours.

- 5 Washed with Et₂O (3X150 ml). Dry the combined extracts over Na₂SO₄ and concentrate in vacuo to a volume of 150 ml. Chill at -20°C overnight, filter to collect the resulting solids, wash with hexane and dry the solids in vacuo to give 5.4 g of the product compound.


- 10 Preparation of compound B. To a stirred solution of the piperazine carboxylic acid derivative (A) (150 mg, 0.33 mmole) and histamine dihydrochloride (73 mg, 0.39 mmole) in CH₂Cl₂ (3 mL) was added DCC (81 mg, 0.39 mmole) and HOBt (53 mg, 0.39 mmole). The mixture was stirred overnight. Solvent was removed in vacuo and the residue was purified by column chromatography with 4-7% MeOH in
15 CH₂Cl₂ to give 98 mg desired product in 55% yield. MS: m/z 546 (MH⁺).

Step1B




- Preparation of compound C. To a stirred solution of the amide (B) (54 mg, 0.098 mmole) in CH₂Cl₂ (2mL) was added triethylamine (14 uL, 0.098 mmole) and p-toluenesulfonyl chloride (19 mg, 0.098 mmole). The reaction was stirred overnight. The reaction was
25 diluted with CH₂Cl₂ (20 mL) and washed with water (20 mL). Organic layer was dried (Na₂SO₄) and solvent removed in vacuo to give 50 mg desired product in 73% yield. MS: m/z 700 (MH⁺).

30

Step 1C


- Preparation of compound D. To a stirred solution of compound **C** (50 mg, 0.072 mmole) in THF (2mL) was added piperidine (1 mL). The reaction was stirred for 2 hours, and solvent was removed in vacuo. The residue was purified by column chromatography with 5% MeOH in CH₂Cl₂ to give 18 mg of the amine in 53% yield. MS: m/z 478 (MH⁺). This amine was dissolved in EtOH (2 mL) and cyclohexylisocyanate (54 uL, 0.37 mmole) was added. The reaction was stirred overnight. Solvent was removed in vacuo and the residue was purified by flash column chromatography with 4% MeOH in CH₂Cl₂ to give quantitative amount of desired product. MS: m/z 603 (MH⁺).

Step1D


- 43 -

4. Preparation of **compound E**. To a stirred solution of the urea (**D**) (23 mg, 0.038 mmole) in CH_2Cl_2 (2mL) was added trifluoroacetic acid (0.5 mL). The mixture was stirred for 20 min. and solvent was removed in vacuo. The residue was pumped on a high vacuum line for 2
- 5 hours and dissolved in CH_3CN (1 mL). To this solution was added 1,2,2,6,6-pentamethylpiperidine (34 μL , 0.19 mmole) and the tricyclic alkyl chloride (**5**) (13 mg, 0.038 mmol). The reaction was stirred overnight. A white precipitate formed. The mixture was dissolved in water (10 mL) and extracted with CH_2Cl_2 (15 mL x 2). The organic layer was dried (Na_2SO_4)
- 10 and solvent was removed in vacuo. The residue was purified by flash column chromatography with 4% MeOH in CH_2Cl_2 to give 15.9 mg desired product in 52% yield. MS: m/z 810 (MH^+).

- 44 -

Step 1E

- 5 5. Preparation of **Compound F** To a stirred solution of **Compound E** (9.5 mg, 0.012 mmole) in MeOH (1 mL) was added HOBT (5 mg, 0.035 mmole). The reaction was stirred overnight. Solvent was removed in vacuo. The residue was purified by flash column chromatography with 5-7 % MeOH in CH₂Cl₂ to give 4.5 mg desired product in 58% yield. MS: m/z 656 (MH⁺).
- 10

EXAMPLE 2

15

- 45 -

1. Preparation of compound **B**. To a stirred solution of the acid (**A**) (1.69g, 3.97 mmole) in CH₂Cl₂ (5 mL) was added pyridine (32 uL, 3.97 mmole) and cyanuric fluoride (669 uL, 7.93 mmole). The reaction was stirred overnight and water (10 mL) was added. The mixture was
5 extracted with CH₂Cl₂ (15 mL x 2). The organic layer was dried (Na₂SO₄) and solvent removed in vacuo. The resulting acid fluoride was dissolved in CH₂Cl₂ (5 mL). To this solution was added triethylamine (732 uL, 5.25 mmole) and 3-amino-methylpyridine (428 uL, 4.2 mmole). The mixture was stirred for 3 hours and then diluted with CH₂Cl₂ (10 mL). the solution
10 was washed with sat. NH₄Cl solution (5 mL). The organic layer was dried (Na₂SO₄) and solvent was removed in vacuo. The residue was purified by flash column chromatography with 2% MeOH in CH₂Cl₂ to give 1.4g desired product in 68% yield. MS: m/z 517 (MH⁺).

1.5 2. Preparation of compound **C**. To a stirred solution of compound(**B**) (581 mg, 1.13 mmole) in CHCl₃ (4 mL) was added
piperidine (2mL). The mixture was stirred for 1 h and solvent was removed in vacuo. The residue was purified by flash column
chromatography with 5-10% MeOH in CH₂Cl₂ to give 320 mg amine in
20 90% yield. The amine (68 mg, 0.231 mmole) was dissolved in CH₂Cl₂ (3 mL). To this solution was added 2,6-lutidine (46 uL, 0.39 mmole) and bromoacetyl bromide (30 uL, 0.35 mmole). The reaction was stirred for 15 min. The reaction was washed with 2% NH₄Cl solution. The aqueous phase was basified by NaHCO₃ and extracted with CH₂Cl₂. The organic
25 layer was dried (Na₂SO₄) and evaporated to give 27 mg product in 28% yield. MS: m/z 415 (M⁺).

3. Preparation of **Compound D**. To a stirred solution of compound **C** (27 mg, 0.066 mmole) in CH₂Cl₂ (2mL) was added
30 trifluoroacetic acid (1 mL). The reaction was stirred for 1 hour and solvent was removed in vacuo. The residue was pumped on a high vacuum for 3 hours then dissolved in DMSO (1 mL). To this solution was added diisopropylethylamine (69 uL, 0.39 mmole). The reaction was stirred for 2 hours, then tricyclic alkyl chloride **5** (27 mg, 0.079 mmole) and
35 diisopropylethylamine (23 uL, 0.13 mmole) was added. The mixture was stirred overnight. Solvent was removed in vacuo. The residue was dissolved in EtOAc (10 mL) and washed with water (5 mL). The organic layer was dried (Na₂SO₄) and solvent removed in vacuo.. The residue

- 46 -


was purified by flash column chromatography with 1 % MeOH in CH₂Cl₂ to give 4 mg product in 13% yield. MS: m/z 542 (MH⁺).

Example 3


5

The following compound was made, using the same procedure as Example 2, except that the R-isomer of Compound A of Example 2 was used:

10



- 47 -

EXAMPLE 4

5

1. Preparation of **B**. To a stirred solution of amine **A** (276 mg, 0.939 mmole) in 2% HOAc/MeOH (2 mL) was added valeraldehyde (110 μL , 1 mmole) and NaBH_3CN . The mixture was stirred overnight.

- 48 -

Solvent was removed in vacuo and 15% NaOH solution was added. The mixture was extracted with CH₂Cl₂ (10mL x 2). The organic layer was dried (Na₂SO₄) and solvent was removed in vacuo. The residue was purified by column chromatography with 2% MeOH in CH₂Cl₂ to give 220 mg product in 65% yield. MS: m/z 365 (MH⁺).


2. Preparation of **C**. To a stirred solution of the amine **B** (101 mg, 0.28 mmole) in DMF (2 mL) was added 2,6-lutidine (43 uL, 0.37 mmole) and chloroacetyl chloride (27 uL, 0.34 mmole). The reaction was stirred for 1 hour and solvent was removed in vacuo. The residue was dissolved in CH₂Cl₂ (10 mL) and washed with 0.5 N NaOH solution. Organic layer was dried (Na₂SO₄) and solvent was removed in vacuo to give 116 mg product in 94% yield. MS: m/z 441 (MH⁺).

3. Preparation of **Compound D**. To a stirred solution of compound **C** (116 mg, 0.26 mmole) in CH₂Cl₂ (3 mL) was added trifluoroacetic acid (1 mL). The reaction was stirred for 1 hour. Solvent was removed in vacuo. The residue was pumped on a high vacuum for 3 hours, then dissolved in DMSO (1mL). To this solution was added diisopropylethylamine (275 uL, 1.58 mmole). The reaction was stirred for 2 hours, then tricyclic alkyl chloride **5** (0.131 mmole) and 1,2,2,6,6-pentamethylpiperidine (94 uL, 0.52 mmole) was added. The mixture was stirred overnight. Solvent was removed in vacuo. The residue was dissolved in EtOAc (10 mL) and washed with water (5 mL). The organic layer was dried (Na₂SO₄) and solvent removed in vacuo. The residue was purified by flash column chromatography with 1 % MeOH in CH₂Cl₂ to give 5.4 mg product in 6.7% yield. MS: m/z 612 (MH⁺).

- 49 -

EXAMPLE 5


5 The following compound was prepared using the same procedures as in Example 4, except that the R isomer of Compound A in Example 4 was used:



10

EXAMPLE 6

15 **Procedure 1. Preparation of 3,10-DIBROMO-8-CHLORO-6,11-DIHYDRO-5H-BENZO[5,6]CYCLOHEPTA [1,2-b]PYRIDIN-11-OL**



20


- 50 -

3,10-DIBROMO-8-CHLORO-5,6-DIHYDRO-11H-BENZO
[5,6]CYCLOHEPTA[1,2-b]PYRIDIN-11-ONE (2gm, 5mm) was
dissolved in 20 ml of methanol. Sodium borohydride (0.6 gm)
was added and the reaction mixture stirred at ambient

5 temperature. After 1 hour the reaction mixture was added to
20 ml of 1N hydrochloric acid and stirred for 5 minutes. 30 ml
of 1N sodium hydroxide was added and the product extracted
with methylenechloride three times. The methylenechloride
layer was dried over magnesium sulfate, filtered, and
10 evaporated to dryness under vacuo to obtain 1.98 gm of title
product. FABMS (M/e+1)=402

**Procedure 2. Preparation of 3,10-DIBROMO-
8,11-DICHLORO-6,11-DIHYDRO-5H-BENZO[5,6]**


15 **CYCLOHEPTA[1,2-b]PYRIDINE**



3,10-DIBROMO-8-CHLORO-6,11-DIHYDRO-5H-
20 BENZO[5,6]CYCLOHEPTA[1,2-b]PYRIDIN-11-OL (1gm, 2.48 mm)
was suspended in 20 ml of methylenechloride under a dry
nitrogen atmosphere. Thionylchloride (1.63gm, 13.71mm) was
added and the reaction mixture stirred for 2 hours. The crude
reaction mixture was evaporated to dryness under vacuo to
25 obtain 1.1 gm of product as the hydrochloride salt. FABMS
(M/e+1)=420

- 51 -


Procedure 3. Preparation of ETHYL 1-(3,10-DIBROMO-8-CHLORO-6,11-DIHYDRO-5H-BENZO[5,6]CYCLOHEPTA[1,2-b]PYRIDIN-11-YL)-3-PIPERAZINE-CARBOXYLATE



3,10-DIBROMO-8,11-DICHLORO-6,11-DIHYDRO-5H-BENZO[5,6]CYCLOHEPTA[1,2-b]PYRIDINE (1.05gm, 2.48mm) was
10 dissolved in 20ml of dry N,N-dimethylformamide under a dry
nitrogen atmosphere. Ethylpiperazine-3-carboxylate (1.177gm,
7.44mm) and diisopropylethylamine (1.28gm, 9.92mm) were
added and the reaction mixture stirred at ambient temperature
for 18 hours. The reaction mixture was added to 100 ml of
15 brine and extracted with 3X150 ml of methylenechloride. The
solvent was removed under vacuo to obtain a solid which was
chromatographed on 100 g of flash silica gel using 50%
ethylacetate/hexanes to obtain 0.895 g of the title product.
FABMS (M/e+1)=542

- 52 -


Procedure 4. Preparation of ETHYL 4-(3,10-DIBROMO-8-CHLORO-6,11-DIHYDRO-5H-BENZO[5,6]CYCLOHEPTA[1,2-b]PYRIDIN-11-YL)-1-(1-OXOPENTYL)-2-PIPERAZINECARBOXYLATE



- ETHYL 1-(3,10-DIBROMO-8-CHLORO-6,11-DIHYDRO-5H-BENZO[5,6]CYCLOHEPTA[1,2-b]PYRIDIN-11-YL)-3-PIPERAZINECARBOXYLATE (0.46gm, 0.85mm) was dissolved in 10 ml of dry N,N-dimethylformamide. Valeric acid (0.153gm, 1.5mm), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (DEC) (0.288gm, 1.5mm), 1-hydroxybenzotriazole (HOBt) (0.203gm, 1.5mm), and N-methylmorpholine (0.5gm, 5mm) were added and the reaction mixture stirred at ambient temperature. After 48 hours, the reaction mixture was added to brine and extracted with 3X150ml of ethylacetate. The combined ethylacetate washes were combined and the solvent evaporated under vacuo to give a gum. The gum was chromatographed on 75gm of flash silica gel using 25% ethylacetate/hexanes as the eluent to obtain 0.45 gm of title product. FABMS (M/e+1)=626

- 53 -

**Procedure 5. Preparation of 4-(3,10-DIBROMO-8-CHLORO-6,11-DIHYDRO-5H-BENZO[5,6]CYCLOHEPTA[1,2-b]PYRIDIN-11-YL)-1-(1-
5 2-PIPERAZINECARBOXYLIC ACID**




ETHYL 4-(3,10-DIBROMO-8-CHLORO-6,11-DIHYDRO-
5H-BENZO[5,6]CYCLOHEPTA[1,2-b]PYRIDIN-11-YL)-1-(1-
10 OXOPENTYL)-2-PIPERAZINECARBOXYLATE (0.4gm, 0.64mm) was
dissolved in 10 mol of ethanol. 5 ml of 1M lithium hydroxide
was added and the reaction mixture stirred for 24 hours. The
pH was adjusted to 4.5 with 10% citric acid, diluted with 50 ml
of water and extracted with 2X100ml of methylenechloride. The
15 methylenechloride extracts were dried over magnesium sulfate,
filtered, and evaporated to dryness to obtain 0.385 gm of title
product. FABMS (M/e+1)=598

20

**Procedure 6. Preparation of 4-(3,10-DIBROMO-8-CHLORO-6,11-DIHYDRO-5H-BENZO[5,6]CYCLOHEPTA[1,2-b]PYRIDIN-11-YL)-N-(3-PYRIDINYLMETHYL)-1-(1-
25 PIPERAZINECARBOXAMIDE**


- 54 -



4-(3,10-DIBROMO-8-CHLORO-6,11-DIHYDRO-5H-
 5 BENZO[5,6]CYCLOHEPTA[1,2-b]PYRIDIN-11-YL)-1-(1-
 OXOPENTYL)-2-PIPERAZINECARBOXYLIC ACID (0.353gm,
 0.59mm) was dissolved in dry N,N-dimethylformamide. 3-
 Aminomethylpyridine (0.127gm, 1.18mm), 1-(3-
 dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (DEC)
 10 (0.266gm, 1.18mm), 1-hydroxybenzotriazole (HOBt) (0.16gm,
 1.18mm), and N-methylmorpholine (0.59gm, 5.9mm) were
 added and the reaction mixture stirred at ambient temperature
 under a dry nitrogen atmosphere for 18 hours. The reaction
 mixture was added to brine and the product extracted with
 15 3X159 ml of ethylacetate. The ethylacetate layers were dried
 over magnesium sulfate and evaporated under vacuo . The
 crude product was chromatographed on a 50gm silica column
 using 2.5% methanol-2M ammonia/methylenechloride and
 increased to 10% to obtain 0.387gm of title product. FABMS
 20 (M/e+1)=691


- 55 -

Procedure 7. Preparation of N,N-di-tert.butoxycarbonyl-3-carboxypiperazine.



3-carboxypiperazine (10gm, 49.2mm) was dissolved
 5 in 200ml of 50% methanol/water and the pH adjusted to 9.5
 with 50% sodium hydroxide. Di-tert.butylidicarbonate (21 gm)
 was added and the pH kept at 9.5 with 1N sodium hydroxide.
 The reaction was monitored by tlc and more di-
 tert.butylidicarbonate added if needed. The reaction mixture
 10 was acidified with conc. Hydrochloric acid to pH=7 and then with
 citric acid to pH 3.8 and extracted with methylenechloride to
 obtain 15.4 gm of solid product.

Procedure 8. Preparation of N,N-di-tert.butoxycarbonyl-3-[4-pyrrolidinone-aminopropionyl]-piperazine



N,N-di-tert.butoxycarbonyl-3-carboxypiperazine
 (2gm, 6.2mm) was dissolved in 20 ml of N,N-
 20 dimethylformamide. 4-Pyrrolidinoneaminopropane (12.4ml,
 12.4mm), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide
 hydrochloride (DEC) (2.38gm, 12.4mm), 1-hydroxybenzotriazole
 (HOBt) (1.68gm, 12.4mm), and N-methylmorpholine (6.82ml,
 62mm) were added and the reaction mixture stirred at ambient
 25 temperature under a dry nitrogen atmosphere for 18 hours.
 The reaction mixture was added to brine and the product
 extracted with 3X159 ml of ethylacetate. The ethylacetate
 layers were dried over magnesium sulfate and evaporated
 under vacuo. The crude product was chromatographed on a
 30 silica gel column using 5% methanol/methylenechloride as the


- 56 -

eluent to obtain the title product which was treated with 30 ml of trifluoroacetic acid for 4 hr at ambient temperature. The trifluoroacetic acid was evaporated to obtain 6 gm of a light brown oil.

5

Procedure 9. Preparation of 4-(3,10-DIBROMO-8-CHLORO-6,11-DIHYDRO-5H-BENZO[5,6]CYCLOHEPTA[1,2-b]PYRIDIN-11-YL)-N-[3-(2-OXO-1-PYRROLIDINYL)PROPYL]-2-PIPERAZINECARBOXAMIDE

10




15

20

3-[4-pyrrolidinone-aminopropionyl]-piperazine ditrifluoroacetic acid salt (6.2mm) is added to a solution of 3,10-DIBROMO-8,11-DICHLORO-6,11-DIHYDRO-5H-BENZO[5,6]CYCLOHEPTA[1,2-b]PYRIDINE (1gm, 2.48mm) in 30 ml of N,N-dimethylformamide and N-methylmorpholine (3.47ml) and stirred for 24 hours. The reaction mixture was added to 100 ml of brine and extracted with 3X150 ml of methylenechloride. The solvent was removed under vacuo to obtain a solid which was chromatographed on a flash silica gel using 2.5%-7.5% methanol/methylenechloride to obtain 0.4 g of the title product. FABMS (M/e+1)=641

- 57 -


Procedure 10. Preparation of 4-(3,10-DIBROMO-8-CHLORO-6,11-DIHYDRO-5H-BENZO[5,6]CYCLOHEPTA[1,2-b]PYRIDIN-11-YL)-1-[(2-METHOXYETHOXY)ACETYL]-N-[3-(2-OXO-1-PYRROLIDINYL)PROPYL]-2-PIPERAZINECARBOXAMIDE




4-(3,10-DIBROMO-8-CHLORO-6,11-DIHYDRO-5H-BENZO[5,6]CYCLOHEPTA[1,2-b]PYRIDIN-11-YL)-N-[3-(2-OXO-1-PYRROLIDINYL)PROPYL]-2-PIPERAZINECARBOXAMIDE (0.064gm) was dissolved in 2ml of N,N-dimethylformamide. 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (DEC) (0.038gm), 1-hydroxybenzotriazole (HOBt) (0.027g), and N-methylmorpholine (0.11ml) were added and the reaction mixture stirred at ambient temperature under a dry nitrogen atmosphere for 18 hours. The reaction mixture was added to brine and the product extracted with ethylacetate. The ethylacetate layers were dried over magnesium sulfate and evaporated under vacuo. The crude product was chromatographed on a silica gel column using 5% methanol/methylenechloride as the eluent to obtain 0.059gm of the title product. FABMS (M/e+1)=713

EXAMPLE 7


- 5 Using substantially the same reaction scheme of Example 1 or 6, and/or the reaction schemes described in the specification above, the following compounds were prepared:




(200)




(201)




(202)



(203)










(204)




(205)


- 59 -




- 60 -




(213)




(214)



(215)









(217)




(219)


- 61 -




- 62 -




(226)




(227)




(228)




(229)




(230)




(231)




(232)




233




234




235




236




237




238




239




240




241



242
















243










244


- 65 -














265




266




267



268



269



270

- 70 -

ASSAYS

FPT IC₅₀ (inhibition of farnesyl protein transferase, in vitro enzyme assay) and COS Cell IC₅₀ (Cell-Based Assay) were
5 determined following the assay procedures described in WO
95/10516, published April 20, 1995. GGPT IC₅₀ (inhibition of
geranylgeranyl protein transferase, in vitro enzyme assay), Cell
Mat Assay, and anti-tumor activity (in vivo anti-tumor studies)
could be determined by the assay procedures described in WO
10 95/10516. The disclosure of WO 95/10516 is incorporated
herein by reference thereto.

Additional assays can be carried out by following
essentially the same procedure as described above, but with
substitution of alternative indicator tumor cell lines in place of
15 the T24-BAG cells. The assays can be conducted using either
DLD-1-BAG human colon carcinoma cells expressing an activated
K-ras gene or SW620-BAG human colon carcinoma cells
expressing an activated K-ras gene. Using other tumor cell lines
known in the art, the activity of the compounds of this invention
20 against other types of cancer cells could be demonstrated.

Soft Agar Assay:

Anchorage-independent growth is a characteristic of
25 tumorigenic cell lines. Human tumor cells are suspended in
growth medium containing 0.3% agarose and an indicated
concentration of a farnesyl transferase inhibitor. The solution is
overlayed onto growth medium solidified with 0.6% agarose
containing the same concentration of farnesyl transferase
30 inhibitor as the top layer. After the top layer is solidified, plates
are incubated for 10-16 days at 37°C under 5% CO₂ to allow
colony outgrowth. After incubation, the colonies are stained by
overlaying the agar with a solution of MTT (3-[4,5-dimethyl-
thiazol-2-yl]-2,5-diphenyltetrazolium bromide, Thiazolyl blue)
35 (1 mg/mL in PBS). Colonies can be counted and the IC₅₀'s can be
determined.

The results are given in the Table below ("nM" represents
nanomolar).

<u>Compound No.</u>	<u>FPT</u> <u>C₅₀ (nM)</u>	<u>COS Cell</u> <u>IC₅₀ (nM)</u>	<u>Soft Agar</u> <u>IC₅₀</u>	<u>GGPTase</u> <u>IC₅₀</u>
200	29			
201	3.2			
202	2.9			
203	3.3			
204	5.5			
205	77			
206	34			
207	55			
208	5.5			
209	47			
210	62			
211	17			
212	31			
213	180			

<u>Compound No.</u>	<u>FPT</u> <u>C₅₀ (nM)</u>	<u>COS Cell</u> <u>IC₅₀ (nM)</u>	<u>Soft Agar</u> <u>IC₅₀</u>	<u>GGPTase</u> <u>IC₅₀</u>
214	39			
215	140			
216 (Procedure 9 of Example 6)	>150			
217	17			
218 (Procedure 10 of Example 6)	48			
219	11			
220	12			
221	50			
222	72			
223	12			
224	10			
225	>130			
226	16			

<u>Compound No.</u>	<u>FPT</u> <u>C₅₀ (nM)</u>	<u>COS Cell</u> <u>IC₅₀ (nM)</u>	<u>Soft Agar</u> <u>IC₅₀</u>	<u>GGPTase</u> <u>IC₅₀</u>
227 (EXAMPLE 1)	7.2 6.7	10-50 30		
228	14, 12, 15	19.6±0.3	18	
229	11.5	59.5	140	
230	1200			
231	2200			
232	>100,000			
233	4.2, 5.0	37±5	57±3	
234	33, 20			
235	93, 101	1100	>1000	
236	26, 28			
237	216, 138			
238	7.4, 6.5	>200	>500	

<u>Compound No.</u>	<u>FPT</u> <u>C₅₀ (nM)</u>	<u>COS Cell</u> <u>IC₅₀ (nM)</u>	<u>Soft Agar</u> <u>IC₅₀</u>	<u>GGPTase</u> <u>IC₅₀</u>
239	22, 12, 28, 16	10-100 25-50 25-50	100-500 100	
240	35, 21	150-200	>1000	>50,000
241	11.5 9.5 9.0	53.5±8.5	83.5 ±2.5	
242	19 16	50-100 127	168±8	31,000
243	250 183			
244	35, 51, 49, 26	250-500	213±40	
245	314, 186			
246	1300 970			
247	8.2 6.7 9.0	75±2.5	87	

- 75 -

<u>Compound No.</u>	<u>FPT</u> <u>C₅₀ (nM)</u>	<u>COS Cell</u> <u>IC₅₀ (nM)</u>	<u>Soft Agar</u> <u>IC₅₀</u>	<u>GGPTase</u> <u>IC₅₀</u>
248	17 19 21			
249	19, 22, 23, 11, 24	<100, 100	50-100	13000 79000
250	4.2 3.0	6.4±0.2	10-50 11	
251	6.3, 5.1, 4.8 5.7	8.6±0.2	38±14	
252	23 11 7.6	28.5±1.5		
253	1000 910	2000		>500,000
254	870 1100			
255	23 12 15	49 94		

<u>Compound No.</u>	<u>FPT</u> <u>C₅₀ (nM)</u>	<u>COS Cell</u> <u>IC₅₀ (nM)</u>	<u>Soft Agar</u> <u>IC₅₀</u>	<u>GGPTase</u> <u>IC₅₀</u>
256	6.7, 7.2 2.9	5.3±0	15.5±3.5	
257	12 14	9.5 12.5	52.5±14.5	
258	10 14	94		
259	211 156	1000 100		
260	7.1 8.9	25	64±14	
261	9.4 8.7	81		
262	4.5 5.2	15.4 25	74.5±4.5	
263	7.8 6.8	10-100 50	50-100 50-100 174	>100,000
264	415 290			
265	7.0 3.6	16 4	52 5.4	

- 77 -

<u>Compound No.</u>	<u>FPT C₅₀ (nM)</u>	<u>COS Cell IC₅₀ (nM)</u>	<u>Soft Agar IC₅₀</u>	<u>GGPTase IC₅₀</u>
266	13.5		41	
	9.5		47	
267	27.3	108	307	
268	13.6	145		
269	4.5±1.4	4		
270	7.3±3nm	0.4	1.5	

- 78 -

For preparing pharmaceutical compositions from the compounds described by this invention, inert, pharmaceutically acceptable carriers can be either solid or liquid. Solid form
5 preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories. The powders and tablets may be comprised of from about 5 to about 70 percent active ingredient. Suitable solid carriers are known in the art, e.g. magnesium carbonate, magnesium stearate, talc, sugar, lactose.
10 Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration.

For preparing suppositories, a low melting wax such as a mixture of fatty acid glycerides or cocoa butter is first melted, and the active ingredient is dispersed homogeneously therein as
15 by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool and thereby solidify.

Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or
20 water-propylene glycol solutions for parenteral injection.

Liquid form preparations may also include solutions for intranasal administration.

Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in
25 combination with a pharmaceutically acceptable carrier, such as an inert compressed gas.

Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration. Such
30 liquid forms include solutions, suspensions and emulsions.

The compounds of the invention may also be deliverable transdermally. The transdermal compositions can take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type
35 as are conventional in the art for this purpose.

Preferably the compound is administered orally.

Preferably, the pharmaceutical preparation is in unit dosage form. In such form, the preparation is subdivided into

- 79 -

unit doses containing appropriate quantities of the active component, e.g., an effective amount to achieve the desired purpose.

5 The quantity of active compound in a unit dose of preparation may be varied or adjusted from about 0.1 mg to 1000 mg, more preferably from about 1 mg. to 300 mg, according to the particular application.

10 The actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under
15 the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day if desired.

The amount and frequency of administration of the compounds of the invention and the pharmaceutically
20 acceptable salts thereof will be regulated according to the judgment of the attending clinician considering such factors as age, condition and size of the patient as well as severity of the symptoms being treated. A typical recommended dosage regimen is oral administration of from 10 mg to 2000 mg/day
25 preferably 10 to 1000 mg/day, in two to four divided doses to block tumor growth. The compounds are non-toxic when administered within this dosage range.

The following are examples of pharmaceutical dosage
30 forms which contain a compound of the invention. The scope of the invention in its pharmaceutical composition aspect is not to be limited by the examples provided.

- 80 -

Pharmaceutical Dosage Form ExamplesEXAMPLE ATablets

No.	Ingredients	mg/tablet	mg/tablet
1.	Active compound	100	500
2.	Lactose USP	122	113
3.	Corn Starch, Food Grade, as a 10% paste in Purified Water	30	40
4.	Corn Starch, Food Grade	45	40
5.	Magnesium Stearate	3	7
Total		300	700

Method of Manufacture

- 5 Mix Item Nos. 1 and 2 in a suitable mixer for 10–15 minutes. Granulate the mixture with Item No. 3. Mill the damp granules through a coarse screen (e.g., 1/4", 0.63 cm) if necessary. Dry the damp granules. Screen the dried granules if necessary and mix with Item No. 4 and mix for 10–15 minutes.
- 10 Add Item No. 5 and mix for 1–3 minutes. Compress the mixture to appropriate size and weigh on a suitable tablet machine.

EXAMPLE BCapsules

15

No.	Ingredient	mg/capsule	mg/capsule
1.	Active compound	100	500
2.	Lactose USP	106	123
3.	Corn Starch, Food Grade	40	70
4.	Magnesium Stearate NF	7	7
Total		253	700

- 81 -

Method of Manufacture


Mix Item Nos. 1, 2 and 3 in a suitable blender for 10-15 minutes. Add Item No. 4 and mix for 1-3 minutes. Fill the
5 mixture into suitable two-piece hard gelatin capsules on a suitable encapsulating machine.

While the present invention has been described in conjunction with the specific embodiments set forth above,
10 many alternatives, modifications and variations thereof will be apparent to those of ordinary skill in the art. All such alternatives, modifications and variations are intended to fall within the spirit and scope of the present invention.

15

WHAT IS CLAIMED IS:


1. A compound of the formula:



- 5 or a pharmaceutically acceptable salt or solvate thereof, wherein:
- a represents N or NO^- ;
- R^a , R^b , R^c , and R^d are the same or different, and are selected from the group consisting of H, halo, alkyl, and alkoxy, with the proviso that at least one, but not more than two of R^a , R^b , R^c and R^d are H;
- the dotted line (---) represents an optional double bond;
- R is selected from the group consisting of H, $-S(O)_2R^1$, $-S(O)_2NR^1R^2$, $-C(O)R^1$, and $-C(O)NR^1R^2$, wherein R^1 and R^2 are independently selected from the group consisting of H, alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, (C₃-C₇) cycloalkyl, cycloalkylalkyl, heterocycloalkyl, substituted alkyl, substituted aryl, substituted arylalkyl, substituted heteroaryl, substituted heteroarylalkyl, substituted (C₃-C₇) cycloalkyl, substituted cycloalkylalkyl, substituted heterocycloalkyl, wherein said substituted groups have one or more substituents selected from: alkyl, alkoxy, aralkyl, heteroarylalkyl, $-NO_2$, alkyloxyalkyl, alkyloxyalkyloxyalkyl, C₃-C₇ cycloalkyl, aryl, $-CN$, heteroaryl, heterocycloalkyl, $=O$, $-OH$, amino, substituted amino, nitro and halo;


- 83 -

R^e and R^f are independently selected from H, alkyl, alkyloxyalkyl, alkyloxyalkyloxyalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, (C₃-C₇) cycloalkyl, cycloalkylalkyl, heterocycloalkyl, substituted alkyl, substituted alkyloxyalkyl, substituted alkyloxyalkyloxyalkyl, substituted aryl, substituted arylalkyl, substituted heteroaryl, substituted heteroarylalkyl, substituted (C₃-C₇) cycloalkyl, substituted cycloalkylalkyl, substituted heterocycloalkyl, wherein said substituted groups have one or more substituents selected from: alkyl, alkoxy, aralkyl, heteroarylalkyl, -NO₂, alkyloxyalkyl, alkyloxyalkyloxyalkyl, C₃-C₇ cycloalkyl, aryl, -CN, heteroaryl, heterocycloalkyl, =O, -OH, amino, substituted amino, nitro and halo; or R^e is selected from the group consisting of H, alkyl and aryl and R^f is represented by $-(CH_2)_n-R^{15}$, wherein n is an integer from 0 to 8 and R^{15} is selected from -C(O)NH₂, -SO₂NH₂, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, optionally substituted by alkyl, alkoxy, aralkyl, heteroarylalkyl, -NO₂, alkyloxyalkyl, alkyloxyalkyloxyalkyl, C₃ - C₇ cycloalkyl, aryl, -CN, heterocycloalkyl, =O, -OH, amino, substituted amino, nitro and halo;

or R^{15} is , wherein B is OH or NH₂ and A is NH, O, NOH or NCN, or R^{15} is NR¹⁶R¹⁷, wherein R¹⁶ is H or alkyl and R¹⁷ is H, alkyl, SO₂CH₃, or C(O)NH₂; or R^e and R^f together with the nitrogen to which they are bound, form a 5 or 6 membered heterocycloalkyl ring which is optionally substituted by OH, NH₂, NHR¹⁶, NHR¹⁷, NR¹⁶R¹⁷, or (CH₂)_nR¹⁸R¹⁹, wherein R¹⁶ and R¹⁷ are as defined above, R¹⁸ is H or C₁-C₆ alkyl, and R¹⁹ is selected from


- 84 -

- H, C₁-C₆ alkyl, substituted alkyl, arylalkyl, acyl (e.g., acetyl, benzoyl, etc.), carboxamido, alkyloxycarbonyl (e.g., methoxycarbonyl), arylalkyloxycarbonyl (e.g., benzyloxycarbonyl), amido derivatives derived from amino acids (e.g., glycine, alanine, serine, etc.), imidate (e.g., phenoxyimidate), cyanide, imidamido (e.g., C(=NH)NH₂, (C=NSO₂NH₂)NH₂, etc.), sulfonamido (e.g., SO₂NH₂, SO₂N(CH₃)₂), sulfonyl (e.g., SO₂CH₃, SO₂C₆H₅, SO₂CH₂C₆H₅, etc.), phosphinate (e.g., P(=O)(CH₃)₂), heterocyclyl and imidamido (e.g., (C=NC₆H₅)C₆H₅), (C=NH)C₆H₅, etc.), wherein n is as defined above; and R^h is H or =O; with the further proviso that when R^h is H and R^b and R^d are





2. The compound of claim 1, wherein R^e is H, R^f is -(CH₂)_nR¹⁵, and R¹⁵ is selected from:

- 85 -



- 86 -





, and
3. The compound of claim 1, wherein a is N
and R^h is H.

5 4. The compound of claim 1, wherein R^a, R^c,
and R^d are halo, and R^b is H.



5. The compound of claim 4, wherein R^a and
R^d are Br and R^c is Cl.

10

6. The compound of claim 2, wherein R is
selected from the group consisting of H, -C(O)(CH₂)₃CH₃,
-S(O)₂CH₃, -C(O)-CH₂-O-(CH₂)₂-O-CH₃, -C(O)-CH₂-OCH₃,
-C(O)NH(CH₂)₃CH₃,



15



and

7. The compound of claim 1, wherein R^h is
O=.

20


8. The compound of claim 7, wherein R^b
and R^d are H, and R^a and R^c are halo.

9. The compound of claim 8, wherein R^a is
Br and R^c is Cl.


25

- 87 -

10. The compound of claim 9, wherein R^e is H and R^f is



5 11. The compound of claim 10, wherein R^f is



12. A method for inhibiting the abnormal growth of cells comprising administering an effective amount of the compound of claim 1.

13. A method for inhibiting the abnormal growth of cells comprising administering an effective amount of the compound of claim 6.

14. A method for inhibiting the abnormal growth of cells comprising administering an effective amount of the compound of claim 7.


15. A method for inhibiting the abnormal growth of cells comprising administering an effective amount of the compound of claim 11.

16. The method of claim 12, wherein the cells inhibited are tumor cells expressing an activated ras oncogene.


17. The method of claim 16, wherein the cells inhibited are pancreatic tumor cells, lung cancer cells, myeloid leukemia tumor cells, thyroid follicular tumor cells, myelodysplastic tumor cells, epidermal carcinoma tumor cells, bladder carcinoma tumor cells, or colon tumor cells.

- 88 -


18. A compound, or a pharmaceutically acceptable salt or solvate thereof, selected from the group consisting of:




233




234




235



236




237




238


- 90 -




239




240




241



242
















243










244


- 91 -














265




266




267



268



269



270

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/11495

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D401/14 A61K31/55 C07D401/04 A61K31/495 A61K31/44
 //(C07D401/14,241:00,221:00,213:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 31478 A (SCHERING CORP ; PHARMACOPEIA INC (US)) 10 October 1996 * see pages 108/109, table 3, examples 41-56 * see the whole document ---	1-18
X	WO 96 31477 A (SCHERING CORP) 10 October 1996 see the whole document ---	1-18
Y	WO 96 31505 A (PHARMACOPEIA INC) 10 October 1996 see the whole document ---	1-18
Y	WO 95 10516 A (SCHERING CORP) 20 April 1995 see the whole document ---	1-18
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

28 September 1998

Date of mailing of the international search report

11. 11. 98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Stellmach, J

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/11495

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 95 10515 A (SCHERING CORP) 20 April 1995 cited in the application see the whole document ---	1-18
Y	BISHOP W R ET AL: "NOVEL TRICYCLIC INHIBITORS OF FARNESYL PROTEIN TRANSFERASE BIOCHEMICAL CHARACTERIZATION AND INHIBITION OF RAS MODIFICATION IN TRANSFECTED COS CELLS" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 51, 22 December 1995, pages 30611-30618, XP002050604 see the whole document ---	1-18
Y	NJOROGE F G ET AL: "NOVEL TRICYCLIC AMINOACETYL AND SULFONAMIDE INHIBITORS OF RAS FARNESYL PROTEIN TRANSFERASE" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 6, no. 24, 1996, pages 2977-2982, XP002056550 see the whole document ---	1-18
Y	BUSS J E ET AL: "FARNESYL TRANSFERASE INHIBITORS: THE SUCCESSES AND SURPRISES OF A NEW CLASS OF POTENTIAL CANCER CHEMOTHERAPEUTICS" CHEMISTRY AND BIOLOGY, vol. 118, no. 2, December 1995, pages 787-791, XP002056549 see the whole document ---	1-18
Y	NJOROGE F G ET AL: "DISCOVERY OF NOVEL NONPEPTIDE TRICYCLIC INHIBITORS OF RAS FARNESYL PROTEIN TRANSFERASE" BIOORGANIC & MEDICINAL CHEMISTRY, vol. 5, no. 1, 1997, pages 101-113, XP002056551 see the whole document -----	1-18

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 98/11495

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 12-17 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/ composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/11495

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9631478 A	10-10-1996	AU 5527996 A	23-10-1996
		CA 2217499 A	10-10-1996
		CZ 9703165 A	18-03-1998
		EP 0819121 A	21-01-1998
		NO 974610 A	08-12-1997
		PL 322689 A	16-02-1998
		US 5801175 A	01-09-1998
WO 9631477 A	10-10-1996	US 5712280 A	27-01-1998
		AU 5432896 A	23-10-1996
		CA 2217477 A	10-10-1996
		EP 0819120 A	21-01-1998
		US 5672611 A	30-09-1997
WO 9631505 A	10-10-1996	AU 5432796 A	23-10-1996
WO 9510516 A	20-04-1995	AU 7970394 A	04-05-1995
		CA 2174104 A	20-04-1995
		EP 0723540 A	31-07-1996
		HU 76056 A	30-06-1997
		JP 8510760 T	12-11-1996
		US 5719148 A	17-02-1998
		US 5714609 A	03-02-1998
		US 5696121 A	09-12-1997
		US 5807853 A	15-09-1998
		ZA 9407971 A	12-07-1996
WO 9510515 A	20-04-1995	AU 7930994 A	04-05-1995
		CA 2174105 A	20-04-1995
		EP 0723538 A	31-07-1996
		HU 76066 A	30-06-1997
		JP 8510759 T	12-11-1996
		SG 48750 A	18-05-1998
		US 5721236 A	24-02-1998
		US 5728703 A	17-03-1998
		ZA 9407970 A	12-07-1996